{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:46:20Z","timestamp":1781045180348,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Hexal AG, a Sandoz company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40259-021-00470-1","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T10:03:24Z","timestamp":1614679404000},"page":"229-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)"],"prefix":"10.1007","volume":"35","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig L.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Gaylis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Jauch-Lembach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Balfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Lemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaib","family":"Hachaichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Brueckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Festini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"issue":"8","key":"470_CR1","first-page":"1681","volume":"26","author":"T Sokka","year":"1999","unstructured":"Sokka T, Kautiainen H, M\u00f6tt\u00f6nen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol. 1999;26(8):1681\u20135.","journal-title":"J Rheumatol."},{"key":"470_CR2","first-page":"280","volume":"137","author":"G Krueger","year":"2001","unstructured":"Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280\u20134.","journal-title":"Arch Dermatol."},{"key":"470_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11926-012-0263-5","volume":"14","author":"WJ Taylor","year":"2012","unstructured":"Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of the WHO international classification of functioning, health, and disability. Curr Rheumatol Rep. 2012;14:369\u201374.","journal-title":"Curr Rheumatol Rep."},{"key":"470_CR4","unstructured":"US Food and Drug Administration. Remicade\u00ae (infliximab) [prescribing information] Horsham, PA: Janssen Biotech, Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103772s5359lbl.pdf. Accessed 3 Dec 2019."},{"key":"470_CR5","unstructured":"US Food and Drug Administration. Enbrel\u00ae (etanercept) [prescribing information] Thousand Oaks, CA: Immunex Corporation. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf. Accessed 03 Dec 2019."},{"key":"470_CR6","unstructured":"US Food and Drug Administration. Humira\u00ae (adalimumab) [Prescribing information] North Chicago, IL: AbbVie Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125057s0110lbl.pdf. Accessed 28 Nov 2019."},{"key":"470_CR7","unstructured":"Hirsch BR, Lyman GH. Biosimilars: a cure to the U.S. health care cost conundrum? Blood Rev. 2014;28:263\u20138."},{"key":"470_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","volume":"72","author":"T Dorner","year":"2013","unstructured":"Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72:322\u20138.","journal-title":"Ann Rheum Dis."},{"key":"470_CR9","doi-asserted-by":"publisher","first-page":"e000019","DOI":"10.1136\/rmdopen-2014-000019","volume":"1","author":"L Gossec","year":"2015","unstructured":"Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1:e000019.","journal-title":"RMD Open."},{"issue":"1","key":"470_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1477-7525-8-89","volume":"8","author":"LC Doward","year":"2010","unstructured":"Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes. 2010;8(1):89.","journal-title":"Health Qual Life Outcomes."},{"key":"470_CR11","unstructured":"US Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: US Food and Drug Administration; 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 28 Nov 2019."},{"key":"470_CR12","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Appendix 2 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man: The Use of Patient-Reported Outcome (PRO) Measures in Oncology Studies EMA\/CHMP\/292464\/2014. London, England: European Medicines Agency; 2016. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed 28 Nov 2019."},{"issue":"12","key":"470_CR13","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","volume":"290","author":"SR Tunis","year":"2003","unstructured":"Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624\u201332.","journal-title":"JAMA"},{"key":"470_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/03009742.2011.566437","volume":"125","author":"T Sokka","year":"2011","unstructured":"Sokka T. Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice. Scand J Rheumatol Suppl. 2011;125:23\u20137.","journal-title":"Scand J Rheumatol Suppl."},{"key":"470_CR15","first-page":"1","volume":"2017","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs update. Ann Rheum Dis. 2016;2017:1\u201318.","journal-title":"Ann Rheum Dis."},{"key":"470_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14712598.2017.1341486","volume":"17","author":"A Inotai","year":"2017","unstructured":"Inotai A, Prins CPJ, Csan\u00e1di M, Vitezic D, Codreanu C, Kal\u00f3 Z. Is there a reason for concern or is it just hype? A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther. 2017;17:915\u201326.","journal-title":"Expert Opin Biol Ther."},{"key":"470_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11926-017-0658-4","volume":"19","author":"R Moots","year":"2017","unstructured":"Moots R, Azevedo V, Coindreau JL, D\u00f6rner T, Mahgoub E, Mysler E, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19:37.","journal-title":"Curr Rheumatol Rep."},{"key":"470_CR18","doi-asserted-by":"crossref","unstructured":"Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677\u201383.","DOI":"10.1517\/14712598.2015.1103733"},{"key":"470_CR19","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, S\u00f8rensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426\u201331.","journal-title":"Ann Rheum Dis."},{"key":"470_CR20","unstructured":"US Food and Drug Administration. Hyrimoz. Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761071lbl.pdf. Accessed 31 Oct 2018."},{"key":"470_CR21","unstructured":"European Medicines Agency. Hyrimoz. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/hyrimoz-epar-public-assessment-report_en.pdf. Accessed 31 Oct 2018."},{"key":"470_CR22","first-page":"1","volume":"30","author":"O von Richter","year":"2019","unstructured":"von Richter O, Lemke L, Haliduola H, Fuhr R, Koernicke T, Schuck E, et al. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opin Biol Ther. 2019;30:1\u20139.","journal-title":"Expert Opin Biol Ther."},{"issue":"3","key":"470_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bjd.16890","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Lacour JP, Fowler JF Jr, Weinberg JM, Gospodinov D, Schuck E, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623\u201331.","journal-title":"Br J Dermatol."},{"issue":"6","key":"470_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40259-020-00447-6","volume":"34","author":"P Wiland","year":"2020","unstructured":"Wiland P, Slawomir J, Dokoupilov\u00e1 E, Brandt-J\u00fcrgens J, Miranda-Lim\u00f3n JM, Cantalejo Moreira M, et al. Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study. Biodrugs. 2020;34(6):809\u201323.","journal-title":"Biodrugs"},{"issue":"4","key":"470_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheum Dis Clin N Am. 2009;35(4):745\u201357.","journal-title":"Rheum Dis Clin N Am."},{"key":"470_CR26","doi-asserted-by":"crossref","unstructured":"van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34\u201340.","DOI":"10.1002\/art.1780390105"},{"issue":"6","key":"470_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/09546630701646172","volume":"18","author":"DA Revicki","year":"2007","unstructured":"Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatol Treat. 2007;18(6):341\u201350.","journal-title":"J Dermatol Treat."},{"issue":"1","key":"470_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"key":"470_CR29","doi-asserted-by":"crossref","unstructured":"Hercogov\u00e1 J, Papp KA, Chyrok V, et al. Quality-of-life outcomes comparing the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Presented at: International Society for Pharmacoeconomics and Outcomes Research 24th Annual International Meeting; May 18-22, 2019; New Orleans, Louisiana. Abstract PBI35. https:\/\/www.centerforbiosimilars.com\/conferences\/ispor-2019\/fresenius-kabis-adalimumab-biosimilar-produces-comparable-qol-improvements-to-humira. Accessed 28 Nov 2019.","DOI":"10.1016\/j.jval.2019.04.117"},{"key":"470_CR30","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1007\/s10067-019-04679-y","volume":"38","author":"CJ Edwards","year":"2019","unstructured":"Edwards CJ, Monnet J, Ullmann M, Vlachos P, Chyrok V, Ghori V. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol. 2019;38:3381\u201390.","journal-title":"Clin Rheumatol."},{"issue":"5","key":"470_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68(5):702\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"470_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti\u2013tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35\u201345.","journal-title":"Arthritis Rheum."},{"key":"470_CR33","first-page":"557","volume":"20","author":"GA Wells","year":"1993","unstructured":"Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective. J Rheumatol. 1993;20:557\u201360.","journal-title":"J Rheumatol."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00470-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-021-00470-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00470-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T10:21:47Z","timestamp":1615458107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-021-00470-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["470"],"URL":"https:\/\/doi.org\/10.1007\/s40259-021-00470-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"28 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Hexal AG, a Sandoz company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Andrew Blauvelt: Received honoraria from Sandoz for scientific consulting. His company, Oregon Medical Research Center, received funds to conduct the clinical study reported herein. Also, he has served as a scientific adviser and\/or clinical study investigator for Sandoz, AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. Craig L. Leonardi: Consultant and\/or advisory board member for AbbVie, Amgen, Boehringer-Ingelheim, Dermira, Eli Lilly, Janssen, Leo, Pfizer, Sandoz, UCB and Vitae; Speaker bureau for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Ortho Dermatologies, Sun Pharmaceuticals, and UCB; Investigator for Actavis, AbbVie, Allergan, Amgen, Boehringer-Ingelheim, Celgene, Coherus, Cellceutix, Corrona, Dermira, Eli Lilly, Galderma, Glenmark, Janssen, Leo Pharma, Merck, Novartis, Novella, Pfizer, Sandoz, Sienna, Stiefel, UCB and Wyeth; writing assistance received from Sandoz. Norman Gaylis: None declared. Julia Jauch Lembach: Employee of Sandoz. Alison Balfour: Employee of Sandoz. Lena Lemke: Employee of Sandoz. Sohaib Hachaichi: Employee of Sandoz. Ines Brueckmann: Employee of Sandoz. Teodora Festini: Employee of Sandoz; stock\/stock options as Sandoz employee, not related to publication. Piotr Wiland: Participation in clinical trial \u2018ADMYRA\u2019, received the fee as principal investigator in his center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The two studies (ADACCESS and ADMYRA) were conducted in accordance with the ethical principles derived from the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practices and in compliance with local regulatory requirements. The study protocols were approved by the Independent Ethics Committee or Institutional Review Board for each center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent before entering the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients provided their consent for their data to be published.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed in relation to PROs are included in this article and the supplementary information files. Anonymized datasets and related documents, such as the statistical analysis plan, protocol, and amendments, can be shared upon reasonable request through a data sharing agreement.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"JJL and LL contributed to the design of the studies. AB, CLL, NG, and PW contributed to the conduct of the clinical studies. JJL, LL, and AB contributed to the analysis and interpretation of the results. SH, IB, and TF discussed the results and contributed to the manuscript. All authors discussed the results and contributed to the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}